Tempus Provider vs CARTOX

The Tempus mobile app gives oncology providers fast and reliable access to patient reports, advanced patient search, and real-time order tracking. View interactive and in-depth patient results with: - Next-generation sequencing results including genomic variants and immunotherapy markers - Sortable and filterable clinical decision support tools including treatment implications and clinical trial(s) matched to patient's clinical and molecular profile - Comprehensive gene descriptions paired with matched therapies - Quick access to your patient’s structured clinical timeline - PDF of your full Tempus report all within the app - Access your patient's data quickly and securely with Touch ID or Face ID - Instantly know when a new report is available via push notifications - Check the status of an order from receipt of specimens through sequencing and report delivery

Cellular therapies can be associated with unique, acute toxicities which can be severe or even fatal if not identified early and treated appropriately. Cytokine Release Syndrome (CRS), the most commonly observed toxicity can range in severity from low-grade constitutional symptoms to high-grade syndrome associated with life-threatening multi-organ disfunction. Neurotoxicity, originally termed CRES (CAR-Related Encephalopathy Syndrome) and now updated to ICANS (Immune effector Cell-Associated Neurotoxicity Syndrome) is the second most-common adverse even and can occur concurrently with CRS. A multi-disciplinary working group was formed to address safety issues for patients receiving cellular therapy which led to the development of new grading methods and treatment algorithms that have been incorporated into the CARTOX mobile app. The CARTOX mobile app assists with grading toxicities, managing toxicities and assists with recommendations regarding appropriate antimicrobial prophylaxis for patients who have received immune effector cell therapy. Users are more easily able to determine if the patient is having cytokine release syndrome or neurotoxicity and to grade those toxicities. Intended audience: Clinicians (physicians, nurse practitioners, physician assistants, pharmacists, nurses) who treat/care for patients receiving immune effector cells.